You are here: Industry Insights > Market News > Morocco’s Sothema to produce China’s Sinopharm vaccine

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Vibegron Intermediate CAS:1421271-01-3

Food Grade Fish Collagen

Vibegron Intermediate CAS:1295539-30-8

Vibegron Intermediate CAS:1426235-01-9

Vibegron Intermediate CAS:163625-46-5

Vibegron Intermediate

Morocco’s Sothema to produce China’s Sinopharm vaccine

firstwordpharmaJuly 06, 2021

Tag: Sothema , COVID-19 , Vaccine

Favorites

Moroccan pharmaceutical firm Sothema will soon start producing 5 million doses of Sinopharm's COVID-19 vaccine in the North African country, as reported in Yahoo!News.

Morocco’s Sothema to produce China’s Sinopharm vaccine

The Moroccan government also signed a deal with Sweden’s Recipharm to set up a plant in Morocco to produce other key vaccines.

The news source said Morocco, which rolled out a COVID-19 vaccination campaign in January, has inoculated more people against the virus than other African countries.

It had administered 19.2 million doses of the Sinopharm and AstraZeneca vaccines as of July 5.

Previous:Psilera Raises $2.5 Million with Oversubscribed Series Seed from Leading Institutional Investors to Accelerate Clinical Pipeline Focused on DMT

Next:Valneva to Host Symposium on COVID-19 and Chikungunya Vaccine Candidates at 31st European Congress of Clinical Microbiology & Infectious Diseases

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Morocco’s Sothema to produce China’s Sinopharm vaccine | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

Morocco’s Sothema to produce China’s Sinopharm vaccine

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may like
More>>

Morocco’s Sothema to produce China’s Sinopharm vaccine

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may likeMore>>

You may like
More>>